Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Source: PRnewswire
Company IPO Announcement: Leads Biolabs Co., Ltd. is set to debut on the Hong Kong Stock Exchange on July 25, 2025, with an IPO priced at HKD 35 per share, aiming to raise approximately USD 189 million for clinical trials, technology advancements, and general corporate purposes.
Innovative Drug Development: The company focuses on developing immuno-oncology therapeutics, boasting a pipeline of 14 drug candidates, including bispecific antibodies and antibody-drug conjugates, with promising early clinical results in treating aggressive cancers like extra-pulmonary neuroendocrine carcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
